Consun Pharmaceutical Group Limited (stock code: 01681) has released a Next Day Disclosure Return for 31 October 2025, indicating that the company’s issued share capital remains unchanged at 847,973,407 shares. The opening and closing balances both stand at 847,973,407 as of 30 and 31 October 2025, respectively.

According to the document, between 14 October and 31 October 2025, the company repurchased a total of 3,000,000 shares for cancellation (not yet cancelled on the reporting date). The highest repurchase price during this period was HKD 15.7565, while the lowest was HKD 14.9148. On 31 October alone, 350,000 shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 15.01 to HKD 15.03, with an aggregate payment of HKD 5,259,040.

Under a repurchase mandate granted on 22 May 2025, Consun Pharmaceutical Group Limited is authorized to buy back up to 85,126,334 shares. As of the disclosure date, 8,195,000 shares in total have been repurchased, representing approximately 9.6269% of the number of issued shares as at the date of the mandate. The announcement states that a moratorium period, in which no new shares may be issued or sold unless approved by the Hong Kong Stock Exchange, will last until 30 November 2025.